NASDAQ · SRRK
Scholar Rock Holding Corporation
$44.18+$0.93 (+2.15%)
Scholar Rock Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
Loading market information…
NASDAQ · CDTX · USD
Stock price, earnings
Quote as of Jan 8, 2026, 02:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cidara Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cidara Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.80-300.0% vs estimate |
| $8.46M+34.33% vs estimate |
| Q4 2023 | Mar 28, 2024 | -$2.28-2,750.0% vs estimate | $13.90M+20.52% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$44.18+$0.93 (+2.15%)
Scholar Rock Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
$28.17-$0.20 (-0.7%)
Adaptive Biotechnologies Corporation’s quoted price sits in the upper half of its reported 52-week range, 8.36% below the high.
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
$31.49$0.00 (0.0%)
Catalyst Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.29% below the high.
$82.84-$0.36 (-0.43%)
Disc Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.74% below the high.
$32.89-$1.07 (-3.15%)
IDEAYA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.94% below the high.
$28.84+$0.06 (+0.21%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.62% below the high.
$22.36-$0.68 (-2.95%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.69% below the high.
